756 related articles for article (PubMed ID: 29181491)
1. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
[TBL] [Abstract][Full Text] [Related]
3. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
[TBL] [Abstract][Full Text] [Related]
4. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
5. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
Piazza F; Winblad B
J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
[TBL] [Abstract][Full Text] [Related]
6. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Chen T; O'Gorman J; Castrillo-Viguera C; Rajagovindan R; Curiale GG; Tian Y; Patel D; von Rosenstiel P; von Hehn C; Salloway S; Hock C; Nitsch RM; Haeberlein SB; Sandrock A; Singhal P
Alzheimers Dement; 2024 May; 20(5):3406-3415. PubMed ID: 38567735
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.
Kastanenka KV; Bussiere T; Shakerdge N; Qian F; Weinreb PH; Rhodes K; Bacskai BJ
J Neurosci; 2016 Dec; 36(50):12549-12558. PubMed ID: 27810931
[TBL] [Abstract][Full Text] [Related]
10. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
Yuksel JM; Noviasky J; Britton S
Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
[No Abstract] [Full Text] [Related]
11. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G
Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853
[TBL] [Abstract][Full Text] [Related]
12. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
Budd Haeberlein S; Aisen PS; Barkhof F; Chalkias S; Chen T; Cohen S; Dent G; Hansson O; Harrison K; von Hehn C; Iwatsubo T; Mallinckrodt C; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; Skordos L; Tian Y; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A
J Prev Alzheimers Dis; 2022; 9(2):197-210. PubMed ID: 35542991
[TBL] [Abstract][Full Text] [Related]
13. Aducanumab for the treatment of Alzheimer's disease.
Tagliapietra M
Drugs Today (Barc); 2022 Oct; 58(10):465-477. PubMed ID: 36305541
[TBL] [Abstract][Full Text] [Related]
14. Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.
Mallinckrodt C; Tian Y; Aisen PS; Barkhof F; Cohen S; Dent G; Hansson O; Harrison K; Iwatsubo T; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; von Hehn C; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A; Chen T; Budd Haeberlein S
J Prev Alzheimers Dis; 2023; 10(2):171-177. PubMed ID: 36946443
[TBL] [Abstract][Full Text] [Related]
15. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.
Arndt JW; Qian F; Smith BA; Quan C; Kilambi KP; Bush MW; Walz T; Pepinsky RB; Bussière T; Hamann S; Cameron TO; Weinreb PH
Sci Rep; 2018 Apr; 8(1):6412. PubMed ID: 29686315
[TBL] [Abstract][Full Text] [Related]
16. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I
CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.
Panza F; Solfrizzi V; Imbimbo BP; Giannini M; Santamato A; Seripa D; Logroscino G
Expert Rev Neurother; 2014 Sep; 14(9):973-86. PubMed ID: 25081412
[TBL] [Abstract][Full Text] [Related]
18. Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.
Loomis SJ; Miller R; Castrillo-Viguera C; Umans K; Cheng W; O'Gorman J; Hughes R; Budd Haeberlein S; Whelan CD
Neurology; 2024 Feb; 102(3):e207919. PubMed ID: 38165296
[TBL] [Abstract][Full Text] [Related]
19. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
Lu D; Dou F; Gao J
Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
[TBL] [Abstract][Full Text] [Related]
20. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
Vaz M; Silva V; Monteiro C; Silvestre S
Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
